Natalizumab Terminated Phase 2 Trials for Rheumatoid Arthritis Treatment

TerminatedTreatment2 IdentifierTitleDrugs
NCT00083759Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
NCT00831649A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201